

This is a preliminary transcript of a Committee hearing. It has not yet been subject to a review process to ensure that the statements within are appropriately attributed to the witness or member of Congress who made them, to determine whether there are any inconsistencies between the statement within and what was actually said at the proceeding, or to make any other corrections to ensure the accuracy of the record.

RPTS ZAMORA

DCMN ROSEN

MARKUP OF:

H.R. 4771, DESIGNER ANABOLIC STEROID CONTROL ACT;

H.R. 4250, SUNSCREEN INNOVATION ACT;

H.R. 594, PAUL D. WELLSTONE MUSCULAR DYSTROPHY COMMUNITY

ASSISTANCE, RESEARCH AND EDUCATION AMENDMENTS OF 2014;

H.R. 669, SUDDEN UNEXPECTED DEATH AND DATA ENHANCEMENT AND
AWARENESS ACT;

H.R. 4290, WAKEFIELD ACT OF 2014;

H.R. 4450, TRAVEL PROMOTION, ENHANCEMENT, AND MODERNIZATION ACT OF
2014; AND

H.R. 5057, EPS SERVICE PARTS ACT OF 2014

MONDAY, JULY 14, 2014

House of Representatives,

Committee on Energy and Commerce,

Washington, D.C.

The committee met, pursuant to call, at 4:12 p.m., in Room

2123, Rayburn House Office Building, Hon. Fred Upton [chairman of the committee] presiding.

Present: Representatives Upton, Whitfield, Pitts, Terry, Burgess, Latta, Bilirakis, Waxman, Dingell, Pallone, Schakowsky, and Castor.

Staff Present: Nick Abraham, Legislative Clerk; Clay Alspach, Counsel, Health; Gary Andres, Staff Director; Sean Bonyun, Communications Director; Leighton Brown, Press Assistant; Patrick Currier, Counsel, Energy & Power; Graham Dufault, Policy Coordinator, CMT; Melissa Froelich, Counsel, CMT; Sydne Harwick, Legislative Clerk; Brittany Havens, Legislative Clerk; Robert Horne, Professional Staff Member, Health; Kirby Howard, Legislative Clerk; Peter Kielty, Deputy General Counsel; Alexa Marrero, Deputy Staff Director; Carly McWilliams, Professional Staff Member, Health; Paul Nagle, Chief Counsel, CMT; Katie Novaria, Professional Staff Member, Health; Macey Sevcic, Press Assistant; Heidi Stirrup, Health Policy Coordinator; John Stone, Counsel, Health; Shannon Weinberg Taylor, Counsel, CMT; Ziky Abablya, Minority Staff Assistant; Michelle Ash, Minority General Counsel; Eric Flamm, Minority FDA Detailee; Hannah Green, Minority Staff Assistant; and Debbie Letter, Minority Staff Assistant.

The Chairman. Sorry I am late. Your planes aren't flying today. The committee will come to order, and the chair recognizes himself for an opening statement. Last week, the Energy and Commerce Committee released its mid-year report which highlighted our bipartisan success in 2014 to promote jobs and economic growth, transform Washington, create a smaller modernized government for the innovation era and protect families, communities and civic initiatives.

This week we look to build upon our strong record of results as we come together to consider seven bills. We will first consider several bills to improve the public health, where the Health Subcommittee under the chairmanship and leadership of Mr. Pitts has been extremely productive.

The Designer Anabolic Steroid Control Act, which was introduced by Mr. Pitts along with Mr. Pallone, would allow the DEA to take swift action to ensure that consumers are not harmed by dangerous products that are being falsely marketed as dietary supplements.

Sunscreen Innovation Act was introduced by Mr. Whitfield and Mr. Dingell and addresses the fact that the FDA has not approved a new sunscreen ingredient in nearly 20 years. The goal of this legislation is to establish a streamlined review process while maintaining strict safety standards by which pending and new sunscreen applications are reviewed in a predictable and transparent manner.

Paul Wellstone Muscular Dystrophy Community Assistance, Research and Education Amendments Act of 2014 was introduced by Health Subcommittee Vice Chair Michael Burgess and Mr. Engel. This bill would address important areas of research to help those living with muscular dystrophy.

The Sudden Unexpected Death and Data Enhancement and Awareness Act introduced by Mr. Pallone would help us better understand and enhanced awareness about sudden, unexpected infants deaths.

Our final public health measure is the Wakefield Act introduced by Mr. Matheson to reauthorize the Emergency Medical Services for Children Program, which focuses on improving the pediatric components of the emergency medical services system.

We will next consider an important bill to boost jobs in the economy, the Travel Promotion, Enhancement, and Modernization Act of 2014 authored by Mr. Bilirakis and Mr. Welch. This bill would reauthorize funding for Brand USA and increase accountability and transparency of the program. Just last week, I held a roundtable in my district to discuss the tremendous benefits, thousands of local jobs and roughly \$1 billion, billion, contributed to the economy annually in Southwest Michigan alone that comes from tourism. Extending Brand USA will market the U.S. as a world-class destination and continue to attract visitors and economic growth to local communities.

Finally, we will consider the EPS Service Parts Act of 2014

introduced by Mr. Gardner and Mr. Tonko. This legislation offers regulatory relief by extending exemptions of a certain external power supply service and spare parts from DOE efficiency standards.

I want to thank everyone for their collective work on these bills and urge their swift approval. And yield for an opening statement to the ranking member of the committee, Mr. Waxman for 5 minutes.

Mr. Waxman. Thank you very much, Mr. Chairman.

Today, the full committee will begin consideration of seven bills. I support passage of all seven, and I will highlight a few now. H.R. 594, the Paul D. Wellstone Muscular Dystrophy Community Assistance Research and Education where MD CARE amendments of 2014 will build upon the work of the Centers for Disease Control and prevention and the NIH to improve research surveillance and educational efforts regarding muscular dystrophy. It will also better incorporate the needs of adults with MD into current work in this area, and I want to acknowledge the efforts of Congressman Engel and Congressman Burgess on this legislation.

H.R. 669, the Sudden Unexpected Death and Data Enhancement and Awareness Act would improve surveillance in data collection on sudden, unexpected infant deaths, sudden unexplained deaths in childhood and stillbirths. Better data on the number and root causes will be critical in advancing our efforts to reduce these tragic deaths, and I would especially like to thank Ranking Member

Pallone for his leadership on this bill.

H.R. 4290, the Wakefield Act of 2014 would reauthorize the Emergency Medical Services for Children Program, which has supported improvements to pediatric emergency care in every U.S. State, territory and freely-associated States. Congressman Matheson should be commended for his work on this measure.

The goal of H.R. 4250, the Sunscreen Innovation Act, is to allow FDA to act more quickly to review marketing applications for new sunscreen ingredients. As a result of the unwieldy review process that FDA is required by current law to follow, there is an unacceptable backlog of these applications that has resulted in a lengthy delay in new products entering the market. I am glad that we are able to work together on a bipartisan basis to create a workable process that will accomplish the goals of submitting access to new sunscreens.

I applaud Mr. Bilirakis and Mr. Welch and sponsors of H.R. 4450 for their ongoing commitment to travel promotion and for putting forward a bill that extends the authorization of the public private partnership that promotes international travel to the U.S.

And finally, Mr. Tonko and Mr. Gardner have introduced a bill related to the Department of Energy's recent efficiency standard for external power supplies which are the little black boxes attached to the cords for laptop computers and other consumer products. This bill would establish an exemption to the new

standards for spare parts. The spare parts would be subject to the 27 standard. DOE will have the ability to limit the exemption in the unlikely event that it is significantly decreasing energy savings. It is a thoughtful, balanced bill. It has broad stakeholder support, and I urge my colleagues to support it.

And Mr. Chairman, I think we have got some good bills before us, and I would like to encourage the members of this committee to endorse them all. Yield back.

The Chairman. Thank you. Chair now recognizes Mr. Pitts for an opening statement.

Mr. Pitts. Thank you, Mr. Chairman. Ranking Member Pallone and I introduced H.R. 4771, the Designer Anabolic Steroid Control Act, DAsCA, to end a loophole that allows designer anabolic steroids to easily be found online, in gyms and even in retail stores. When taken by consumers, designer steroids, which are class 3 controlled substances, can cause serious medical harm, including liver injury and increased risk of heart attack and stroke. They may also lead to aggression, hostility and addiction.

Designer steroids are produced by reverse engineering existing illegal steroids and then slightly modifying their chemical composition so the resulting product is not on the DEA's list of controlled substances. DAsCA will help protect consumers from these harmful products by giving DEA the tools and authority to properly classify designer steroids as controlled substances

and increase criminal penalties for importing, manufacturing or distributing them under false labels.

DASCA would immediately place a number of known designer anabolic steroids on the list of controlled substances. It would grant the DEA authority to temporarily schedule new designer steroids on the controlled substances list for 24 months with the possibility of a 6-month extension so that if bad actors develop new variations, these products can be removed from the market immediately, create new penalties for importing and manufacturing distributing anabolic steroids under false labels and authorize the attorney general to publish a list of products containing an anabolic steroid that are not properly labeled.

DASCA is supported by the American Herbal Products Association, the Consumer Healthcare Products Association, the Council for Responsible Nutrition, the Natural Products Association and the United Natural Products Alliance. And I urge my colleagues to support this bill, and I yield back.

The Chairman. Gentleman yields back. The chair will recognize the gentleman from the great State of Michigan, Mr. Dingell, for an opening statement for 3 minutes.

Mr. Dingell. Mr. Chairman, I thank you for your courtesy. I also commend you for the markup and for your leadership in this matter. I am most pleased that the committee is continuing a long and proud tradition of passing public health bills in a bipartisan manner. This is what our constituents want of us, and I believe

we are setting an example that the rest of the Congress can and should follow.

While I support all the bills before us today, I am going to focus my remarks on H.R. 4250, the Sunscreen Innovation Act. I am sorry that it was necessary for us to proceed this way on this legislation, and I am sorry that Food and Drug did not move with better and more expeditious efforts, because they could have and indeed should have. But the committee came in and saw to it that the matter was properly addressed and in a bipartisan manner.

I am pleased that the committee then is considering this legislation. The Nation is facing a skin cancer epidemic. And it is inexcusable that sunscreen sold in the United States today do not offer the same level of protection as sunscreens sold in Europe and that some sunscreen ingredients have been waiting review by FDA for over a decade. We need a predictable, transparent and workable framework for FDA to approve sunscreen ingredients, and I am confident we have achieved this important goal. I am afraid that this issue will come before us again, but I am prepared to address it in the same way we did this time if we can't get Food and Drug to do the job that they should.

For the first time, FDA will have strict statutory deadlines for the review of sunscreen ingredients, which will empower the agency to act on these applications that have been pending for far too long. The legislation also sets up a viable framework for FDA to consider new applications that are submitted after enactment.

And I want to thank my colleague and friend, Mr. Whitfield, for his leadership and for his hard work on the legislation.

I also want to thank you, Chairman Upton and Chairman Pitts and Ranking Members Waxman and Pallone, for their support and contributions to the legislation throughout the entire process. The staff has done a superb job and has worked long and hard to see to it that the matter has been brought to the point where it is.

Every day we don't, act Americans will not have access to the most effective sunscreen ingredients, and the skin cancer epidemic will continue. I hope and I am confident that this legislation will make it to the President's desk by the end of the year.

Once again, Mr. Chairman, I thank you for holding this important markup today. I want to thank my colleagues who worked so hard on this, and I want to commend the staff, both of the members who worked on this and of the committee, the majority and the minority, for the efforts that they put into it. Thank you, Mr. Chairman.

Mr. Pitts. [Presiding.] Chair thanks the gentleman. Now recognize the gentleman from Nebraska, Mr. Terry, 3 minutes for opening statement.

Mr. Terry. Thank you, Mr. Chairman. And while there are several really good health bills, I am talking about the one that is not the health bill, and that is H.R. 4450, the Travel Promotion, Enhancement, and Modernization Act, also known as TPA.

This is an effort to recruit foreign visitors to come to the United States to spend their entertainment dollars.

Certainly, areas like Orlando or Hollywood or are famous around the world. And the Trade Promotion Act, which is up for reauthorization next year, so one point we could make is that we are working in advance to reauthorize this, but it is a program that uses fees from foreign visitors' visas as well as the tourism hotel industries that will then match those dollars voluntarily.

I want to thank Gus Bilirakis for jumping on this ride, strapping in, putting the bar down, taking it for a ride and bringing it back into a nice, slow stop. And not only did he take control of this bill, but he then sought bipartisan participation in here, and during our markup last week, it passed 22 to zero, and I want to congratulate the gentleman from Florida, Mr. Bilirakis, on doing such a great job.

But what this is is a jobs bill. It is a jobs bill because the travel industry is such a huge economic driver. Some of the statistics from the travel, the TPA directly in 2013 saw travelers that invested \$3.4 billion supporting 53,181 jobs. And it is not just the cool places like Orlando with Disneyland or Disney World -- well, Disneyland in California; actually, Nebraska gets its share, where we have ecotourism, where people come from all over the world to see the cranes migrate, other ecotourism.

But the Strategic Air & Space Museum are number one rated, and the United States Zoo all get their share because of TPA. But

it really does come back to the 53,181 jobs directly resulting from tourism supported by the TPA, so that is why it passed unanimously. And look forward to seeing it at the full markup, and once again, thank Peter Welch and Gus Bilirakis, and I yield back.

Mr. Pitts. Gentleman yields back. Chair recognizes the Ranking Member of the Health Subcommittee, Mr. Pallone, for 3 minutes for an opening statement.

Mr. Pallone. Thank you, Mr. Chairman.

Today, we will consider five important public health bills that address a wide array of issues, including children's health, muscular dystrophy, sunscreen products and illegal anabolic steroids. H.R. 4290 sponsored by Representatives Matheson and Peter King would reauthorize the Emergency Medical Services for Children Program through 2019 to improve pediatric emergency care, and the bill also supports research and quality improvement efforts.

We will also consider my bill, H.R. 669, to help us better understand and enhance awareness about stillbirths and sudden, unexpected infant deaths. And I am very pleased that we are taking this critical step in helping the families in this country that suffer such tragic events.

H.R. 594, introduced by Representatives Burgess and Engel, would reauthorize important programs to those with muscular dystrophy including important research. The bill reflects new

scientific advances as well as the needs of adults living with muscular dystrophy.

We know there are public health consequences, sometimes deadly, of excessive sun exposure because of the lag of action by the FDA on new ingredients. H.R. 4250 would create a process by which both pending applications and new applications can be reviewed in a timely manner and the bill is the result of extensive work by staff, FDA and stakeholders to establish acceptable timelines for sunscreen evaluation and approval process.

And lastly, we will consider the Designer Anabolic Steroid Control Act which would allow the DEA to take swift action to ensure the consumers, especially young athletes, are not harmed by dangerous products that are being falsely marketed as dietary supplements. Anabolic steroids are synthetic forms of testosterone which are class 3 controlled substances.

To skirt the law, however, a number of bad actors are altering the chemical structure of such substances and promoting these designer products for their own anabolic effects. The bill would give DEA additional tools to crack down on the dangerous practice, and I am pleased to have worked on another health bill with Chairman Pitts, and I thank him for his collaboration.

Additionally, I lend my support to H.R. 5057, the EPS Service Parts Act; and H.R. 4450, the Travel Promotion, Enhancement, and Modernization Act. The latter is especially important to the

Jersey Shore, which I represent, as would help further the promotion of tourism to the United States.

Mr. Chairman, I want to thank the various members of our committee for their leadership in advancing these important bills, and I yield back.

Mr. Pitts. Chair thanks the gentleman, and now recognizes the Vice Chairman of the Sub Health Committee, Dr. Burgess, 3 minutes for opening statement.

Dr. Burgess. Thank you, Mr. Chairman. I do want to say that I am supporting all of the bills that we are marking up today. I do want to comment on the bipartisan legislation with Mr. Engel, H.R. 594, the Muscular Dystrophy Community Assistance, Research and Education Amendments of 2013. This bill makes targeted updates and improvements to legislation first passed by this committee in 2001 and reauthorized in 2008.

These efforts have passed on voice votes and passed overwhelmingly on the floor. This legislation is supported by the totality of the muscular dystrophy community with over 20 organizations writing letters of support which are all part of the subcommittee record. Since its enactment, this law has successfully used limited Federal resources to improve clinical care across the muscular dystrophies. Muscular dystrophy is not a single disease but a group of genetic disorders.

Important to note that this bill provides no additional authorizations of appropriations and proposes a small set of

improvements intended to ensure that the program is focused on the most critical areas and that the funding is being provided that reflects current scientific and medical knowledge. I thank the committee for its bipartisan work on these bills and urge all members to support, and I yield back my time.

Mr. Pitts. Chair thanks the gentleman. Now recognize the gentlelady from Illinois, Ms. Schakowsky, 3 minutes for opening statement.

Ms. Schakowsky. Thank you, Mr. Chairman. Well, this is a great day for our committee, all these bipartisan pieces of legislation. I will support each of the seven bills we will consider tomorrow. The Designer Anabolic Steroid Control Act would ensure that manufacturers can no longer produce and distribute anabolic steroids to the public under the guise of dietary supplements. The Sunscreen Innovation Act would help Americans protect themselves from prolonged sun exposure by increasing the pace at which new safe and effective sunscreens can enter the U.S. market.

The three public health bills, the MD CARE amendments of 2014, the Sudden Unexpected Death and Data Enhancement and Awareness Act, and the Wakefield Act highlight the importance of Federal investments in public health programs to families and communities across the country. And the EPS Service Parts Act takes commonsense steps to phase in energy efficiency requirements for external power supplies.

As the ranking member of the Commerce, Manufacturing, and Trade Subcommittee, I am particularly pleased with H.R. 4450, the Travel Promotion, Enhancement, and Modernization Act. H.R. 4450, reauthorized the Brand USA program, a public-private partnership to encourage foreign travel to the United States. I strongly support Brand USA's mission of promoting U.S. tourism, and I have heard from travel and tourism professionals across my district and around Chicago area about the need to reauthorize the program this year. I would like to thank Congressman Bilirakis and Welch for leading this bipartisan effort.

In last week's subcommittee markup, I offered an amendment to further improve accountability within the program. The amendment directs the Department of Commerce to establish specific publicly-available time frames and conditions for revisions and resolution of disagreements related to its in-kind contribution policy. It also requires the disclosure of Brand USA individual expenditures exceeding \$500,000.

And finally, the amendment expands on Mr. Bilirakis and Mr. Welch's efforts to strengthen Brand USA requiring the development of new metrics to monitor the performance of the program. By fully understanding the effectiveness of various efforts, Brand USA will be able to maximize its impact in attracting international tourism. Brand USA's continued long-term success is essential to communities around the country and the 1.3 million Americans whose jobs are supported by foreign travel.

This is a very strong bill, and I look forward to its swift passage tomorrow. And I yield back.

Mr. Pitts. Chair thanks the gentlelady. Now recognizes the gentleman from Ohio, Mr. Latta, 3 minutes for opening statement.

Mr. Latta. Thank you, Mr. Chairman, and thank you for holding today's markup. I want to specifically mention my support for H.R. 4250, the Sunscreen Innovation Act. This legislation would establish a new review process for sunscreen ingredients by the FDA whereby pending a new application to be reviewed in a predictable and transparent manner. In the bill, there would also be an opportunity for the FDA to hear input by experts in the public towards this review process.

This bill is extremely important as melanoma is a prominent form of cancer in this country, and Americans should have access to the best products available to protect themselves from this terrible disease. Over the past 40 years, melanoma has increased 800 percent among young women and 400 percent among young men. Every year, there are 2 million Americans diagnosed with some form of skin cancer.

Tragically, my home State of Ohio ranks in the top 10 for the highest melanoma death rates in the country. One of the causes of risk in the rise of skin cancer is the over exposure to ultraviolet radiation. I am very concerned that a new over-the-counter sunscreen ingredient has not been approved by the FDA since the 1990s, and there are currently eight new sunscreen

ingredient submissions that have been pending before the FDA for 12 years, none of which have received final approval.

Sunscreen with new ingredients has been available in foreign markets including Europe, Canada, Asia and South America for the last 15 years. American companies produce these ingredients but are forced to export their products overseas because of the regulatory inaction by the FDA. If an ingredient has been deemed safe and effective for many years in Europe, why is it not being given the same chance for success in the United States? H.R. 4250 is a simple way of alleviating the current backlog of sunscreen ingredients and streamlining the process which will, most importantly, protect American families from skin cancer and save lives.

In addition, I am also pleased to see H.R. 5057, the EPS Service Parts Act of 2014 included in the markup. This committee has produced a host of small but important energy efficiency bills that make a big difference for impacted shareholders. The proposed technical fix is not only the product of successful bipartisan collaboration but also good governance proposal protects EPS, external power supplies, service parts manufacturers from unnecessary costs.

I urge my colleagues to support these bills, and Mr. Chairman, I thank you and I yield back.

Mr. Pitts. Chair thanks the gentleman. Now recognizes the gentlelady from Florida, Ms. Castor, 3 minutes for opening

statement.

Ms. Castor. Thank you. Mr. Chairman, in my home State of Florida, travel and tourism means jobs and it means economic growth. That is why it is so important that we are taking up the reauthorization of the Travel Promotion Act, and I am proud to be an original cosponsor of the bill. And I want to thank my colleague, Congressman Gus Bilirakis, for introducing the legislation. He and I fly out of the best airport in the country together, Tampa International Airport, and we value the world-class treatment visitors to our area receive the minute they step off of the plane.

People come to Tampa and St. Petersburg to go to Busch Gardens, the Florida Aquarium, to visit some of the world's best beaches, go fishing or drink cafe con leche in historic Ybor City and enjoy everything the Gulf Coast has to offer. Travel and tourism in Florida did take a very serious hit after the BP oil disaster and after the economic collapse. But lately, it has been making a major comeback, and we want to do everything we can to support it.

In 2010, I was proud to help pass the Travel Promotion Act and create Brand USA to promote America as a premier travel destination to international visitors. Brand USA is a great, private-public partnership model that returns \$47 for every \$1 spent on travel promotion. And we have seen the results, over 1 million more visitors spending over \$3 billion at U.S.

businesses, most of them small businesses. All of this activity has a major economic impact.

In 2013, we had a record number of visitors to Florida. In Hillsborough and Pinellas counties that I represent, we saw over \$12 billion of economic activity tied to tourism alone. Visit Tampa Bay and Visit St. Pete/Clearwater and the small businesses in my community could see a real boost with the help of the Travel Promotion Act and more international visitors. Reauthorizing Brand USA will help.

We still have more work to do in reforming our visa waiver program to help our international visitors come to the United States. And if any of my colleagues are not cosponsors of the JOLT Act, I highly encourage you to take a look and join today. The Jobs Originated Through Launching Travel Act is part of comprehensive immigration reform. It is part of the bill that passed the Senate. It has been blocked here in the House, unfortunately.

I am cosponsoring the JOLT Act because it will create jobs and travel and tourism, reauthorize Brand USA and expand the trusted traveler programs and increases the number of U.S. Customs and Border Protection officers. Last year, the head of Marriott International called for passage, and at this time, I would like to insert into the record his letter that says travel industry supports immigration reform.

Mr. Pitts. Without objection, so ordered.

[The letter follows:]

***** COMMITTEE INSERT *****

Ms. Castor. Thank you, Mr. Chairman. Again, I would like to thank you, Mr. Chairman, and my colleagues for your support of this important legislation and urge all of my colleagues to support H.R. 4450, the Travel Promotion, Enhancement, and Modernization Act. I yield back.

Mr. Pitts. Chair thanks the gentlelady. Now recognize the gentleman from Florida, Mr. Bilirakis, 3 minutes for opening statement.

Mr. Bilirakis. Thank you, Mr. Chairman, I appreciate it, and I appreciate your consideration of H.R. 4450, the Travel Promotion, Enhancement, and Modernization Act, which would reauthorize Brand USA for a limited time. It has numerous accountability measures and strengthens the transparency of the public-private partnership that promotes increased tourism to the United States.

Last week, this bill passed the Subcommittee on Commerce, Manufacturing and Trade unanimously by a vote of 22 to zero. Passage of H.R. 4450 will be good for the economy. It is a jobs bill, Mr. Chairman. A recent analysis performed by the independent firm Oxford Economics estimated that fiscal year 2013 Brand USA generated 1.1 million additional international visitors who spent an estimated \$3.4 billion generating economic revenue and supporting job creation in communities across America.

Brand USA does not impose a cost upon the Federal Government. In fact, it has helped reduce the deficit during the last 2 fiscal

years and is expected to continue to do so.

Federal tax dollars are not used to fund Brand USA. I will say it again: Federal tax dollars are not used to fund Brand USA. Brand USA is supported by international visitors and in private sector contribution, voluntary, I might add. After it receives contributions from the private sector, Brand USA can only collect up to \$100 million in matching funds from fees paid by foreign travelers. Amounts collected in excess of that cap are returned to the Treasury for deficit reduction.

Finally, given the benefits to the economy across the State lines as well as the competitive nature of foreign competitors in travel promotion, Congress is well within its authority under the commerce clause to extend the Travel Promotion Act. Small State and local tourism offices and local small businesses across America are some of the strongest supporters of the Travel Promotion Act and benefit greatly from international tourism. Brand USA helps bridge these communities and opens up new markets to American competition.

I appreciate consideration of this legislation which, again, several commentators this week have noted includes important reforms. This bill improves an already-existing partnership. I urge support of this prudent and narrow reauthorization of the Travel Promotion Act, and I want to thank my primary cosponsor, Mr. Peter Welch, for his leadership and I urge passage.

Thank you very much, Mr. Chairman, and I yield back the

balance of my time.

Mr. Pitts. Chair thanks the gentleman. All members' written opening statements will be made a part of the record. The chair now calls up H.R. 4771 and asks the clerk to report.

The Clerk. H.R. 4771, to amend the Controlled Substances Act to more effectively regulate anabolic steroids.

Mr. Pitts. Without objection, the first reading of the bill is dispensed with and the bill will be open for amendment at any point. So ordered.

For the information to members, we are now on H.R. 4771. The committee will reconvene tomorrow at 10:00 a.m., and I remind members that the chair will give priority recognition to amendments offered on a bipartisan basis. I look forward to seeing all of you tomorrow, and without objection, the committee stands in recess.

[Whereupon, at 4:46 p.m., the committee was adjourned, to be reconvened Tuesday, July 15, at 10:00 a.m.]